Key Highlights
- After a Phase 3 leukemia trial reported median survival of 24.0 months versus 14.7 months for the control arm, SELLAS Life Sciences (NASDAQ:SLS) was up 163.69%, at USD 19.70, during the session on Tuesday, November 17, 2026.
- At USD 2.66, up 46.15%, Aytu BioPharma (NASDAQ:AYTU) sits roughly 1.5% below the cash tender offer of USD 2.70 a share made by Rosemont Pharmaceuticals Holdings (calculated), a deal valued near USD 56 million.
- Cingulate (NASDAQ:CING) gained 24.53% to USD 4.67, while Gain Therapeutics (NASDAQ:GANX) added 23.38% to reach USD 1.16, yet company releases showed no November 17 announcement from either.
- Greenwich LifeSciences (NASDAQ:GLSI) was up 23.26% at USD 16.96 following a November 17 notice that the San Antonio Breast Cancer Symposium accepted two abstracts, although its filing includes going-concern language.
SELLAS Life Sciences (NASDAQ:SLS): Phase 3 Survival Result Fuels a 163.69% Surge
At USD 19.70, SELLAS Life Sciences (NASDAQ:SLS) was trading up 163.69%, which points to a prior close near USD 7.47 (calculated). A November 17, 2026 report said the Phase 3 REGAL trial hit its overall survival goal in acute myeloid leukemia. Median survival with galinpepimut-S, a Vaccine directed at the WT1 protein, was 24.0 months compared with 14.7 months, and the hazard ratio was 0.59 at a p-value of 0.035. The trial randomized 126 patients and reached a prespecified 80 deaths. Cash stood at USD 134.7 million on September 30, 2026, and a Biologics License Application is planned for the first half of 2027. The open-label design, a p-value only just below 0.05 and a small sample are the main risks, and regulators could ask for more data. Secondary analyses continue, a medical conference presentation is planned, and a rally this large can be followed by a financing.
Aytu BioPharma (NASDAQ:AYTU): A USD 2.70 Cash Bid Acts as a Ceiling
Rosemont Pharmaceuticals Holdings agreed on November 16, 2026 to buy Aytu BioPharma (NASDAQ:AYTU) at a cash price of USD 2.70 per share, roughly USD 56 million on a fully diluted basis, and the stock was trading up 46.15% at USD 2.66. A tender offer comes first, then a merger, with a close targeted for late December 2026 and a majority of shares needing to tender. Published coverage that rests on one source and is unverified cites an outside date of February 14, 2027 and a 51.7% premium over the November 13 close. First-quarter fiscal Revenue was USD 14.8 million versus USD 13.9 million, with a USD 3.9 million net loss, while ADHD portfolio revenue slid from USD 13.2 million to USD 7.7 million. An unmet condition or slippage past the outside date is the central risk, and the premium figures stay unverified until tender documents are filed.
Cingulate (NASDAQ:CING): Up 24.53% With No Announcement That Day
In intraday market data, shares of Cingulate (NASDAQ:CING) were up 24.53%, at USD 4.67, yet no company announcement dated November 17, 2026 accounts for the rise. Published coverage said the stock fell 12.8% on the November 13 report date, so some of the rise may be a rebound; that is an inference rather than a reported cause. On June 1, 2026 the FDA issued a complete response letter for CTx-1301, the company's ADHD tablet, pointing to Manufacturing information, and the company says no clinical safety or efficacy concerns were raised. A resubmission is expected between December 2026 and January 2027. Cash of about USD 23.2 million compares with a third-quarter net loss of USD 7.7 million, and more at-the-market sales would dilute shareholders. A launch could start in the third quarter of 2027, depending on the FDA review.
Gain Therapeutics (NASDAQ:GANX): Up 23.38% With No Verified Trigger
Nothing dated November 17, 2026 turned up in the newsroom or filings of Gain Therapeutics (NASDAQ:GANX), whose shares were changing hands at USD 1.16 in intraday market data, up 23.38%. Its most recent item was the November 10 third-quarter report, with a net loss that narrowed from USD 5.28 million to USD 3.16 million. Cash fell from USD 20.84 million at December 31, 2025 to USD 11.70 million at September 30, 2026. The Phase 2 start for rexaceract, a Parkinson's candidate, slipped from the third quarter of 2026 to the first quarter of 2027. USD 11.70 million equals roughly 3.7 quarters at the latest loss rate, a calculated figure and not company guidance, which makes financing a risk. Valued at about USD 51 million (calculated), the stock can move on few trades, spreads may be wide and quoted moves can reverse. In the fourth quarter of 2026 a second candidate is due to name its first target indication.
Greenwich LifeSciences (NASDAQ:GLSI): Poster Acceptances Alongside Going-Concern Language
Greenwich LifeSciences (NASDAQ:GLSI), valued near USD 249 million (calculated), was up 23.26% at USD 16.96. It announced on November 17, 2026 that the San Antonio Breast Cancer Symposium accepted two abstracts and two posters, which are to be shown on December 9. No new trial data came with the release, so the matching dates are a coincidence of timing, not a stated cause. GLSI-100 is in the Phase III FLAMINGO-01 trial and holds Fast Track designation. Cash of USD 8.88 million at June 30, 2026 sat against a USD 9.61 million loss over six months, and the filing flags substantial doubt that the company can continue as a going concern. At-the-market sales raised USD 9.34 million net at an average of USD 25.36, so more sales would dilute holders, and a rally can make them easier. Trial results of this type are years off.
Where Things Stand
Just two of the five moves rest on a clear, dated catalyst. SELLAS Life Sciences (NASDAQ:SLS) advanced because of pivotal survival data. Aytu BioPharma (NASDAQ:AYTU) climbed on a cash Takeover bid. No company announcement was found for Cingulate (NASDAQ:CING). The same goes for Gain Therapeutics (NASDAQ:GANX). A conference notice that carried no results accompanied the advance at Greenwich LifeSciences (NASDAQ:GLSI). Every name still has a hurdle ahead, whether regulatory review at SELLAS, a closing at Aytu, a resubmission at Cingulate, funding at Gain or cash at Greenwich, so none of these gains settles the outcome. Prices in companies this size can swing on a handful of trades, and quoted moves can reverse.
_11_17_2026_18_59_44_560836.jpg)





Please wait processing your request...